Business EPS was EUR 1.79, up 15.7% at CER and up 17.0% reported. Reports Q1 IRFS net sales EUR 9.9B, up 10.8% reported and up 9.7% at CER.

Sanofi SNY reported first-quarter 2025 adjusted earnings of 94 cents per American depositary share, which beat the Zacks Consensus Estimate of 90 cents per share. Earnings of €1.79 per share rose 17.0 ...

The board of directors of Sanofi (SNY) have proposed an annual dividend of €3.92 per share, an increase of 4.26% from prior dividend of €3.76 per share.

In 2025, sales are anticipated to grow by a mid-to-high single-digit percentage at CER 5. Sanofi confirms the expectation of a strong rebound in business EPS with growth at a low double-digit ...

Sanofi confirms the expectation of a strong rebound in business EPS with growth at a low double-digit percentage at CER (before share buyback)6 • Sanofi intends to complete a share buyback program in ...

The approval allows Imfinzi to be used in... Sanofi’s New Hemophilia Drug Qfitlia Gains FDA Approval with Breakthrough Bimonthly Dosing The U.S. Food and Drug Administration (FDA) has approved ...

Shares of Sanofi (NASDAQ:SNY) and Roche (OTCQX:RHHBY) were flat in European trading on Thursday after the EU pharma giants ...

BofA raised the firm’s price target on Alnylam (ALNY) to $328 from $325 and keeps a Buy rating on the shares. The firm updated models in ...